Jazz Presents New Xywav Data at SLEEP 2026 Meeting
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DUBLIN, Ireland, June 16, 2026 Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new...
PROVIDENCE, R.I., June 15, 2026 Nabsys 2.0, LLC has announced a strategic research collaboration with Leiden University Medical Center...
SAN DIEGO, June 15, 2026 Neurocrine Biosciences has unveiled new two-year data from its Phase 3 CAHtalyst® Adult study,...
BOSTON, Massachusetts, USA and GHENT, Belgium, June 10, 2026 Orionis Biosciences and Novartis have announced a major multi-year strategic...
TEL AVIV, Israel, June 10, 2026 Teva Pharmaceutical Industries Ltd. has completed its acquisition of Emalex Biosciences, strengthening its...
INDIANAPOLIS, United States, June 10, 2026 Eli Lilly and Company has launched a nationwide awareness campaign featuring NBA legend...
LOUVAIN-LA-NEUVE, Belgium – June 9, 2026 IBA (Ion Beam Applications), the global leader in proton therapy technology, has achieved...
London, UK – June 8, 2026 Engitix Ltd., a biotechnology company specializing in extracellular matrix (ECM)-driven drug discovery, has...
INDIANAPOLIS, USA – June 8, 2026 Eli Lilly and Company has reported compelling new Phase 3 clinical data showing...
BOULDER, Colorado, June 5, 2026 Ambrosia Biosciences has unveiled promising preclinical data for AMB-702, its novel oral small-molecule GLP-1...
